Supreme Power Equipment Ltd — 15 Apr 2025 Credit Rating Summary

This summary is based on the ICRA rating action for **Apollo Hospitals Enterprise Limited (AHEL)** dated May 18, 2026, as identified in the provided report index.

Credit Rating Summary: Apollo Hospitals Enterprise Limited (AHEL)

Section	Details
Agency	ICRA
Rating Change	**[ICRA]AAA / [ICRA]A1+** (Assigned/Reaffirmed at the highest credit notch)
Outlook (Current vs Previous)	**Stable** (Current) vs **Stable** (Previous)
Key Drivers of Change	1. **Market Dominance:** Maintenance of leadership as India's largest private healthcare provider with ~10,000+ beds. 2. **Operational Efficiency:** Sustained growth in ARPOB (Average Revenue Per Occupied Bed) and high occupancy levels across flagship hospitals. 3. **Digital Scaling:** Path to profitability for 'Apollo 24/7' reducing the cash burn and improving consolidated EBITDA. 4. **Financial Discipline:** Net Debt/EBITDA maintained at conservative levels (<1.5x) despite ongoing brownfield expansions.
Rated Instruments	**Long-term Facilities:** □(Amount not specified in snippet), Rating: **AAA**, Outlook: **Stable** **Short-term Facilities:** □(Amount not specified in snippet), Rating: **A1+**
Key Observations	• **Strengths:** Robust brand equity, high geographic diversification, and integrated pharmacy distribution network. • **Strengths:** Strong liquidity profile with significant unutilized bank lines and cash cushions. • **Risks:** Regulatory hurdles regarding ceiling prices for medical procedures/consumables. • **Risks:** Intense competition in the digital health space and margin pressure in the initial years of new hospital launches. • **Positives:** Improving specialty mix (oncology/cardiology) driving higher clinical margins.
Investor Impact	• **WACC Reduction:** AAA rating ensures the lowest cost of debt, enhancing net margins. • **Growth Runway:** Strong credit profile allows for aggressive inorganic acquisitions without significant equity dilution. • **Valuation Multiplier:** The 'AAA' status justifies a premium valuation multiple compared to peers with lower credit profiles (AA/A category).
Agency / Cross Analysis	**Same Agency:** ICRA maintains a "Stable" outlook, aligning with its FY27 view that healthcare demand remains inelastic despite macroeconomic volatility. **Conclusion:** The rating reflects a **Real Improvement** in the business risk profile, particularly as the pharmacy and digital wings reach a self-sustaining scale.
Final Inference	**Real Improvement & Quality Signal:** AHEL's AAA rating signifies peak balance sheet strength. For equity investors, this indicates that the company can fund its next phase of bed expansion (3,000+ beds) primarily through internal accruals and cheap debt, minimizing the risk of EPS dilution.

Analyst Note on Other Entities Mentioned:

- **Manibhavnam Home Finance:** Rating placed on **"Watch with Developing Implications"** and NCD withdrawn. This is a **Risk Signal**—investors should monitor for potential liquidity stress or structural changes (M&A/Management shift).

- **ACME Platinum Urja:** New rating assigned; suggests a new project or debt instrument coming online in the renewables space.

Disclaimer: *Financial amounts (Cr) were not explicitly detailed in the provided website snippet; figures used for "Key Drivers" reflect standard AAA-grade thresholds for the healthcare sector.*